Add BrightSurf on Google Email

Vaccine targeting KRAS in pancreatic and colorectal cancer shows promise

A new off-the-shelf vaccine has shown encouraging early results as a potential treatment for patients with pancreatic or colorectal cancer who have certain KRAS gene mutations. The vaccine appears to stimulate the immune system to create cancer-fighting cells, delaying cancer recurrence in some patients.

SourceMemorial Sloan Kettering Cancer Center·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateFeb 2, 2024

Immune cells lose ‘killer instinct’ in cancerous tumors – but functionality can be re-awakened

Researchers discovered that immune cells called natural killer cells rapidly lose their functionality when entering solid tumours, adopting a dormant state. However, targeting the IL-15 pathway can restore NK cell activity and improve tumor control. This breakthrough could pave the way for new cancer treatments.

SourceUniversity of Birmingham·JournalNature Communications·TypeExperimental study·DateFeb 2, 2024

Clarifying the cause of Guillain-Barré Syndrome

Researchers uncover pivotal aspect of GBS pathophysiology, revealing autoreactive T lymphocytes invade nerve tissue and target myelin. The findings provide novel insights into understanding GBS, opening avenues for targeted therapies for specific subtypes.

SourceETH Zurich·JournalNature·TypeExperimental study·DateJan 19, 2024

A new targeted treatment calms the cytokine storm

Researchers from Osaka University have discovered a novel treatment strategy for cytokine storm, a serious inflammatory syndrome triggered by an infection or severe burn. The new approach involves blocking IL-6 receptor signaling with a short-term antibody, minimizing treatment side effects and preventing vascular damage.

SourceOsaka University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJan 17, 2024

Incurable autoimmune disease Systemic Lupus Erythematosus (SLE): New genetic findings open up perspectives for future therapeutic approaches

Researchers identified a mutation in the UNC93B1 gene in patients with SLE, which leads to selective overactivation of TLR7 receptor and results in an immune attack on normal cells. The findings demonstrate that UNC93B1 controls the activity of specific nucleic acid receptors, such as TLR7, thereby preventing autoimmunity.

SourceTechnische Universität Dresden·JournalScience Immunology·DateJan 12, 2024

Study shows genetically modified pluripotent stem cells may evade immunological rejection after transplantation

Researchers have successfully genetically modified pluripotent stem cells to evade immune recognition, offering a viable path forward for pluripotent stem cell-based therapies. The study's findings suggest that these engineered stem cells could pave the way for new treatments for diseases such as Type 1 diabetes and macular degeneration.

SourceUniversity of Arizona Health Sciences·JournalStem Cell Reports·TypeExperimental study·DateJan 11, 2024

Risk model based on routine blood work predicts treatment response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.

SourceUniversity of Eastern Finland·JournalBMC Cancer·DateJan 3, 2024

A novel angle on type 1 diabetes: RNA editing disruption mimics early-stage disease with no involvement of virus

A recent study by the Hebrew University proposes a new etiology for early stages of type 1 diabetes, attributing it to disrupted RNA editing within pancreatic beta cells. This perspective challenges long-held beliefs about viral involvement, suggesting potential implications for treatments and cures.

SourceThe Hebrew University of Jerusalem·JournalCell Metabolism·TypeExperimental study·DateDec 25, 2023

New type of antibody shows promise against multiple forms of flu virus

Researchers have identified a novel class of antibodies capable of neutralizing both certain H3 and H1 strains of the flu virus, with potential applications in developing more broadly protective flu vaccines. The findings could also contribute to reducing reliance on chicken egg-based manufacturing methods.

SourcePLOS·JournalPLOS Biology·TypeExperimental study·DateDec 21, 2023

Immune system plays crucial step in creating blood stem cells

A microbial sensor, Nod1, plays a crucial role in the development of blood stem cells. The discovery could lead to the creation of patient-derived blood stem cells, eliminating the need for bone marrow transplants and improving lives of leukemia, lymphoma, and anemia patients. Researchers are continuing to study the complex interaction...

SourceIowa State University·JournalNature Communications·TypeExperimental study·DateDec 19, 2023

B cell deficient patients gain protective T cell immunity following SARS-CoV-2 vaccination and infection, study finds

Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.

SourceRagon Institute of MGH, MIT and Harvard·JournalScience Translational Medicine·TypeObservational study·DateDec 18, 2023

Toothbrushing tied to lower rates of pneumonia among hospitalized patients

A new study found that daily toothbrushing among hospitalized patients is associated with lower rates of hospital-acquired pneumonia and ICU mortality. The study, which analyzed data from over 2,700 patients, also showed that toothbrushing was linked to shorter durations of mechanical ventilation and ICU length of stay.

SourceBrigham and Women's Hospital·JournalJAMA Internal Medicine·TypeRandomized controlled/clinical trial·DateDec 18, 2023

How the immune system fights to keep herpes at bay

Researchers have discovered key mechanisms by which the host immune system blocks viral infection in the cell's nucleus, including the role of signaling proteins called interferons and host protein IFI16. These findings could lead to new treatments for herpesviruses and other nuclear DNA viruses.

SourceHarvard Medical School·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateDec 14, 2023

Patients can interrupt treatment of immune-supressing medicines for two weeks in order to boost immunity provided by COVID-19 booster vaccine, finds major study

A major study found that patients with inflammatory conditions can boost their antibody response to a COVID-19 booster vaccination by interrupting their treatment for two weeks. The improved protection lasts for six months, and patients who interrupted treatment reported more flare-ups but most were self-managed.

SourceUniversity of Nottingham·JournalThe Lancet Rheumatology·TypeRandomized controlled/clinical trial·DateDec 12, 2023

T cells tackle new 'Pirola' SARS-CoV-2 variant

Researchers at La Jolla Institute for Immunology found that most T cells can still target epitopes on the new Pirola variant, suggesting people may be able to mount a response against it. The study's findings provide positive news in the fight against SARS-CoV-2, emphasizing the importance of vaccination with updated vaccines.

SourceLa Jolla Institute for Immunology·JournalCell Host & Microbe·TypeData/statistical analysis·DateDec 8, 2023

More than skin-deep

A team of Kyoto University researchers found that macrophages produce granulomas through a hyperactive metabolic pathway called the pentose phosphate pathway. Inhibition of this pathway showed therapeutic efficacy in reducing granuloma formation in vitro and in mouse tissue models.

SourceKyoto University·JournalJournal of Clinical Investigation·TypeExperimental study·DateDec 6, 2023

Progress toward improved vaccines

A research team has introduced a spectrum of potential adjuvants, including α-GalCer analogs with improved activity. The new compounds trigger stronger immune responses in mice, with some demonstrating better adjuvant properties than previously optimized variants.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateNov 30, 2023

Fish IgM structure sheds light on antibody evolution, study finds

Researchers analyzed fish IgM to understand its structure and how it differs from human antibodies. They discovered a unique folding mechanism that allows the antibody to assemble without a joining chain, enabling it to bind antigens and interact with its environment.

SourceCarl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign·JournalNature Communications·TypeExperimental study·DateNov 27, 2023

Research shows infants exposed to certain biologics during pregnancy can safely receive rotavirus vaccine

A Canadian study found that infants exposed to biologic agents during pregnancy have normal immune development and can safely receive the rotavirus vaccine. The study, involving 191 infants across six sites in Canada, aimed to change vaccination guidelines to protect more babies from severe illness.

SourceUniversity of Calgary·JournalThe Lancet Child & Adolescent Health·TypeObservational study·DateNov 23, 2023

Anti-rheumatic drugs could prevent thyroid disease

Researchers found that immunomodulatory drugs used to treat rheumatoid arthritis can reduce the risk of autoimmune thyroid diseases. Patients treated with these drugs had a 46% lower risk of developing an autoimmune thyroid disease compared to those without rheumatoid arthritis.

SourceKarolinska Institutet·JournalJournal of Internal Medicine·TypeObservational study·DateNov 22, 2023

Cancer stem cells trigger macrophage aging

Researchers at Hokkaido University found that cancer stem cells cause macrophages to age, suppressing their antitumor activity. Supplementing mice with nicotinamide mononucleotide restored macrophage function and prevented tumor growth.

SourceHokkaido University·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateNov 14, 2023